Guangzhou Welman Pharmaceutical Wins Patent Authorization Lawsuit
This article was originally published in PharmAsia News
Executive Summary
The antibiotic piperacillin-shubatanna patent authorization lawsuit between Shanghai Asia Pioneer Pharmaceutical and Guangzhou Welman Pharmaceutical recently came to a close. The China International Economic and Trade Arbitration Commission ruled that Asia Pioneer has infringed on Welman's patent and needs to pay RMB 4.7 million ($687,838) compensation. In 2005, Welman transferred its piperacillin-shubatanna patent to Asia Pioneer at RMB 80 million, the highest patent transfer fee in China's pharmaceutical industry to date. However, Welman withdrew its patent from Asia Pioneer two years later for not paying the patent royalty, but the latter continued producing and selling the drug, leading to Welman's lawsuit. Analysts believe the heated fight can be attributed to the drug being included in the national medical insurance in 2005, which offers a promising market. (Click here for more - Chinese language)
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.